share_log

藥明生物：二零二三年度報告

WUXI BIO: Annual Report 2023

Hong Kong Stock Exchange ·  Apr 29 05:15
Summary by Moomoo AI
WuXi Biologics（药明生物）於2024年4月23日公布了2023年度年報。報告顯示，公司2023年收入達到人民幣17,034.3百萬元，較2022年增長11.6%。毛利微增1.5%，至人民幣6,827.9百萬元。然而，歸屬於股東的利潤下降23.1%，為人民幣3,399.7百萬元。全年歸屬於股東的綜合收益為人民幣3,190.9百萬元。董事會未建議派發截至2023年12月31日止年度的末期股息。股本變動包括回購34,769,000股。公司維持高標準的企業治理，董事會領導並監督公司事務。審計重點包括CRDMO合同的收入確認以及對蘇州生物子公司的商譽減值評估。公司擁有風險管理機制，並維持有...展開全部
WuXi Biologics（药明生物）於2024年4月23日公布了2023年度年報。報告顯示，公司2023年收入達到人民幣17,034.3百萬元，較2022年增長11.6%。毛利微增1.5%，至人民幣6,827.9百萬元。然而，歸屬於股東的利潤下降23.1%，為人民幣3,399.7百萬元。全年歸屬於股東的綜合收益為人民幣3,190.9百萬元。董事會未建議派發截至2023年12月31日止年度的末期股息。股本變動包括回購34,769,000股。公司維持高標準的企業治理，董事會領導並監督公司事務。審計重點包括CRDMO合同的收入確認以及對蘇州生物子公司的商譽減值評估。公司擁有風險管理機制，並維持有效的內部控制系統，內部審計功能支持董事會和管理層。公司鼓勵股東參與年度股東大會，並與股東和投資者保持開放溝通。對於子公司和投資，公司按成本計價並減去已識別的減值損失。對於聯營公司的投資則通過損益按公允價值計量。公司於租賃開始日確認使用權資產和租賃負債。根據在中國成立的子公司要求，向法定儲備撥款。
WuXi Biologics (Pharmaceutical Biologics) published its 2023 Annual Report on April 23, 2024. The report showed that the company's revenue reached RMB17,034.3 million in 2023, an increase of 11.6% compared to 2022. Gross profit increased by 1.5% to RMB6,827.9 million. However, profit attributable to shareholders fell 23.1% to RMB3,399.7 million. Comprehensive income attributable to shareholders for the full year was RMB3,190.9 million. The Board of Directors has not proposed the distribution of a final dividend for the year ended 31 December 2023. The change in share capital includes the repurchase of 34,769,000 shares. The company maintains a high standard of corporate governance and the Board of Directors leads and supervises the company's affairs. AUDIT HIGHLIGHTS INCLUDE REVENUE CONFIRMATION OF CRDMO CONTRACTS AND A REPUTATIONAL IMPAIRMENT ASSESSMENT OF SUZHOU BIO SUBSIDIARIES. The company has...Show More
WuXi Biologics (Pharmaceutical Biologics) published its 2023 Annual Report on April 23, 2024. The report showed that the company's revenue reached RMB17,034.3 million in 2023, an increase of 11.6% compared to 2022. Gross profit increased by 1.5% to RMB6,827.9 million. However, profit attributable to shareholders fell 23.1% to RMB3,399.7 million. Comprehensive income attributable to shareholders for the full year was RMB3,190.9 million. The Board of Directors has not proposed the distribution of a final dividend for the year ended 31 December 2023. The change in share capital includes the repurchase of 34,769,000 shares. The company maintains a high standard of corporate governance and the Board of Directors leads and supervises the company's affairs. AUDIT HIGHLIGHTS INCLUDE REVENUE CONFIRMATION OF CRDMO CONTRACTS AND A REPUTATIONAL IMPAIRMENT ASSESSMENT OF SUZHOU BIO SUBSIDIARIES. The company has a risk management mechanism and maintains an effective internal control system, and internal audit functions support the board and management. The Company encourages shareholders to attend the Annual General Meeting and to maintain open communication with shareholders and investors. For subsidiaries and investments, companies price according to cost and subtract recognized impairment losses. Investments in joint ventures are measured by profit and loss at fair value. The Company confirms the right of use assets and lease liabilities on the lease commencement date. Grant to Statutory Reserves at the request of a subsidiary incorporated in China.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more